Gemifloxacin mesylate

Gemifloxacin mesylate (CAS No.: 210353-53-0) is a synthetic small molecule antibacterial agent in the fluoroquinolone class and is broadly categorized as an anti infective research compound for microbiology, bacterial physiology, and early stage anti bacterial drug discovery workflows, with no biological origin as a natural product and with a functional profile defined by inhibition of bacterial type II topoisomerases, primarily DNA gyrase and topoisomerase IV, leading to suppression of DNA replication, disruption of chromosome topology control, and consequent inhibition of bacterial proliferation; consistent with this mechanism, it is commonly characterized by strong in vitro activity against Gram positive organisms including streptococci and staphylococci while retaining activity across selected Gram negative species, and published susceptibility patterns for this class are generally reported in low micromolar to sub micromolar equivalent potency windows depending on strain background, resistance genotype, inoculum conditions, and assay format, with activity metrics in screening programs typically interpreted through MIC based panels rather than single pathway reporter outputs, making the compound suitable for mechanism informed profiling of topoisomerase dependent antibacterial responses, resistance selection studies, and comparative benchmarking against other quinolone analogs in cell based bacterial culture systems; in translationally oriented preclinical research, it may also be incorporated into controlled infection model designs in animals to study exposure response relationships and bacterial burden dynamics, where the concentrations or doses used in experiments typically depend on specific experimental designs and research objectives.